Completed from United Kingdom
I found the Pharmacovigilance course surprisingly engaging and down‑to‑earth. The tutors used plain language and real examples from the UK market, which made complex concepts like signal detection feel approachable. I walked away knowing how to navigate VigiBase and put together a concise Periodic Safety Update Report (PSUR) for my team. The slide deck and downloadable templates were spot‑on – I’ve already started using the adverse event follow‑up checklist in my daily work. It wasn’t perfect, but the practical focus and friendly vibe made it a solid learning experience.
The Pharmacovigilance course at Stanmore School of Business delivered exactly what I needed to meet my professional development goals. The curriculum covered the FDA's adverse event reporting requirements in depth, and the hands‑on exercises using the FDA MedWatch system helped me master case assessment and data entry. I especially appreciated the real‑world case studies that illustrated how to draft a complete Individual Case Safety Report (ICSR). The course materials were current, well‑organized, and referenced the latest ICH guidelines, which made it easy to apply what I learned directly to my role as a drug safety associate. Overall, the learning experience was seamless and highly relevant—I'm now confident in handling regulatory submissions and have already applied these skills to a recent product safety review at my company.
Wow! This course blew me away with its energy and depth. From day one, the instructors sparked excitement about pharmacovigilance, and I quickly learned to run signal detection analyses using the WHO's VigiFlow platform. I applied the new skills to a live project at my pharma company, identifying a potential safety signal that led to a timely label update. The reading list featured the latest ICH E2D guidelines, and the interactive simulations of risk‑management plans were incredibly realistic. The overall experience was exhilarating – I feel fully equipped to lead safety monitoring initiatives and can’t wait to share what I learned with my colleagues.
The Pharmacovigilance program was meticulously structured, covering every facet from basic terminology to advanced risk management planning. I particularly benefited from the detailed module on developing a Risk Management Plan (RMP) for a new biologic, which included step‑by‑step templates and real case examples from African markets. The course also provided extensive practice with the safety database Argus, enabling me to generate accurate aggregate safety reports. While the content was dense, the supplementary video lectures and downloadable SOPs helped me digest the material thoroughly. My overall satisfaction is high; I now possess a comprehensive toolkit that aligns with both local regulatory expectations and global standards.
